A novel approach to removing excess fluid through the skin and a new strategy to prevent right ventricular failure after LVAD implantation are among the highlights of the January issue of the Journal ...

Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer baseAdvance SeaStar Medical’s ...

HIC built world-class cardiovascular care in Colombia by fusing together global standards, innovation and human-centered ...

The clinical-stage genetic medicine company reported that LX2020 was generally well tolerated across ten participants, with ...

A new meta-analysis finds no clear long-term cardiovascular benefit from beta-blockers after myocardial infarction in ...

Patients with pre-existing high blood pressure are more likely to be susceptible to heart damage caused by anthracyclines, the most widely used chemotherapy drugs for cancer treatment for more than 30 ...

Morgans Scott Power positive of renewed momentum in the healthcare sector, which has risen 0.7% in the week ending January 16 ...

Shares of Lexeo Therapeutics (NASDAQ:LXEO) dropped about 17% on Monday after the company published interim Phase I/II results ...

Medtronic this week launched its OmniaSecure defibrillation lead in the U.S., describing it as the world's smallest.

Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...

“Rick is an accomplished executive with a proven track record in the medical device industry,” said Jason Spees, Chief Executive Officer at Impulse Dynamics®. “I am thrilled to welcome Rick to the ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...